[go: up one dir, main page]

AR017752A1 - Composicion de matriz solida y porosa, metodo para su preparacion y metodo para la liberacion controlada de un agente terapeutico utilizando dichamatriz - Google Patents

Composicion de matriz solida y porosa, metodo para su preparacion y metodo para la liberacion controlada de un agente terapeutico utilizando dichamatriz

Info

Publication number
AR017752A1
AR017752A1 ARP980102217A ARP980102217A AR017752A1 AR 017752 A1 AR017752 A1 AR 017752A1 AR P980102217 A ARP980102217 A AR P980102217A AR P980102217 A ARP980102217 A AR P980102217A AR 017752 A1 AR017752 A1 AR 017752A1
Authority
AR
Argentina
Prior art keywords
composition
solid
porous matrix
gas
therapeutic
Prior art date
Application number
ARP980102217A
Other languages
English (en)
Original Assignee
Imarx Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imarx Pharmaceutical Corp filed Critical Imarx Pharmaceutical Corp
Publication of AR017752A1 publication Critical patent/AR017752A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La matriz solida y porosa comprende un solvente y un tensioactivo en combinacion con un agente bioactivo. El solvente y el tensioactivo pueden formarvesículas cuya aglomeracion forma la matriz. Eventualmente la composicion puede comprender un gas o un precursor gaseoso. La emulsion puede secarsey luego reconstituirse en una solucion acuosa u orgánica. El método para preparar una matriz solida y porosa combina un solvente, un tensioactivoy un terapéutico para formar una emulsion, y procesa la emulsion por secado regulado, o agitacion regulada y secado regulado para formar una matrizsolida y porosa. La matriz solida y porosa obtenida puede comprender también un gas o un precursor de gas y agregarse a un medio de resuspension.El método para elsuministro regulado del terapéutico con blanco determinado en una region del paciente comprende aplicar al paciente una composicion quetiene una matriz solida y porosa que comprende un solvente, un tensioactivo, un terapéutico y un gas o precursor de gas, monitorear la composicion usandouna fuente de energía para determinar la presencia de la composicion en la region, y liberar el terapéutico de la composicion en la region utilizandola fuente de energía.
ARP980102217A 1997-05-13 1998-05-13 Composicion de matriz solida y porosa, metodo para su preparacion y metodo para la liberacion controlada de un agente terapeutico utilizando dichamatriz AR017752A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4637997P 1997-05-13 1997-05-13
US09/075,477 US20020039594A1 (en) 1997-05-13 1998-05-11 Solid porous matrices and methods of making and using the same

Publications (1)

Publication Number Publication Date
AR017752A1 true AR017752A1 (es) 2001-10-24

Family

ID=26723856

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102217A AR017752A1 (es) 1997-05-13 1998-05-13 Composicion de matriz solida y porosa, metodo para su preparacion y metodo para la liberacion controlada de un agente terapeutico utilizando dichamatriz

Country Status (5)

Country Link
US (3) US20020039594A1 (es)
EP (1) EP0983060A4 (es)
AR (1) AR017752A1 (es)
AU (1) AU7378798A (es)
WO (1) WO1998051282A1 (es)

Families Citing this family (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US20020055702A1 (en) * 1998-02-10 2002-05-09 Anthony Atala Ultrasound-mediated drug delivery
PT1666026E (pt) † 1999-02-08 2012-03-15 Intarcia Therapeutics Inc Veículos viscosos não aquosos biocompatíveis monofásicos e métodos para a preparação dos mesmos
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6254852B1 (en) 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
BR0013276A (pt) * 1999-08-09 2004-08-03 Pharmacia Italia Spa Formulação farmacêutica para uso parenteral que compreende fosfato de estramustina, como ingrediente ativo
EP1202670A4 (en) * 1999-08-13 2004-11-10 Point Biomedical Corp HOLLOW MICROSPHERES WITH CONTROLLED FRAGILITY FOR MEDICAL USE
GB9921954D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
GB9921958D0 (en) 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8235919B2 (en) * 2001-01-12 2012-08-07 Celleration, Inc. Ultrasonic method and device for wound treatment
FR2823675B1 (fr) * 2001-04-19 2004-03-12 Inst Nat Sante Rech Med Biomateriaux avec recouvrements bioactifs
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods
JP2004535431A (ja) * 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
US6458769B1 (en) * 2001-06-25 2002-10-01 Astrazeneca Ab Amorphous compound
DE60226613D1 (de) * 2001-08-16 2008-06-26 Baxter Int Darreichungsformen welche mikropartikel und treibgas enthalten
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
JP2005508369A (ja) * 2001-10-18 2005-03-31 ベリオン　インコーポレイテッド マイクロカプセルマトリックス微小球、吸収を促進する薬剤組成物および方法
US20030109824A1 (en) * 2001-11-07 2003-06-12 Microvena Corporation Distal protection device with local drug delivery to maintain patency
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
IL162001A0 (en) * 2001-11-14 2005-11-20 Alza Corp Catheter injectable depot compositions and uses thereof
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
AU2003202872A1 (en) * 2002-01-04 2003-07-24 Nuccon Technologies Inc. Preparation of nano-sized crystals
US7300670B2 (en) * 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
US6835387B2 (en) 2002-06-11 2004-12-28 Scimed Life Systems, Inc. Sustained release of superoxide dismutase mimics from implantable or insertable medical devices
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
BR0313539A (pt) * 2002-07-31 2005-06-21 Alza Corp Composições depósito de polìmero multimodais injetáveis e seus usos
DE60226282T2 (de) * 2002-07-31 2009-09-17 Alza Corp., Mountain View Injizierbare depotzusammensetzungen und deren verwendung
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
CA2498798A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
GB0224986D0 (en) * 2002-10-28 2002-12-04 Smith & Nephew Apparatus
JP2006509502A (ja) * 2002-12-11 2006-03-23 フェローサン アクティーゼルスカブ スワブとしてのゼラチンベースの材料
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
AU2003302274A1 (en) * 2002-12-31 2004-07-29 Novartis Ag Aerosolizable pharmaceutical formulation for fungal infection therapy
US7494544B2 (en) * 2003-01-23 2009-02-24 Bj Services Company Polymer shell encapsulated gas as a cement expansion additive
US7543642B2 (en) * 2003-01-24 2009-06-09 Halliburton Energy Services, Inc. Cement compositions containing flexible, compressible beads and methods of cementing in subterranean formations
CA2543458A1 (en) * 2003-10-24 2005-05-12 Josef Rettenmaier & Soehne Gmbh & Co., Kg Process for co-spray drying agents with dry silicified mcc
US11298453B2 (en) 2003-10-28 2022-04-12 Smith & Nephew Plc Apparatus and method for wound cleansing with actives
DE602005022554D1 (de) * 2004-01-30 2010-09-09 Ferrosan As Hämostatische sprays und zusammensetzungen
US10413644B2 (en) 2004-04-27 2019-09-17 Smith & Nephew Plc Wound treatment apparatus and method
US7753894B2 (en) 2004-04-27 2010-07-13 Smith & Nephew Plc Wound cleansing apparatus with stress
GB0409446D0 (en) 2004-04-28 2004-06-02 Smith & Nephew Apparatus
US8529548B2 (en) 2004-04-27 2013-09-10 Smith & Nephew Plc Wound treatment apparatus and method
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US7399490B2 (en) * 2004-05-17 2008-07-15 Lean For Life, Inc. Compositions containing a nopal cactus isolate and method for making same
US8021684B2 (en) * 2004-07-09 2011-09-20 Ferrosan Medical Devices A/S Haemostatic composition comprising hyaluronic acid
US20090142404A1 (en) * 2004-08-31 2009-06-04 Pfizer Inc Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
US8750983B2 (en) 2004-09-20 2014-06-10 P Tech, Llc Therapeutic system
WO2006044996A2 (en) * 2004-10-15 2006-04-27 The Trustees Of Columbia University In The City Of New York System and method for automated boundary detection of body structures
WO2006047663A2 (en) * 2004-10-26 2006-05-04 The University Of North Carolina At Chapel Hill Aerosol generation of therapeutic agents
US8156829B2 (en) * 2004-10-26 2012-04-17 The University Of North Carolina At Chapel Hill Methods of acoustic measurement and control of pharmaceutical sprays
ATE526365T1 (de) 2004-12-23 2011-10-15 Dow Corning Vernetzbare saccharid-siloxan-zusammensetzungen und daraus gebildete netzwerke, überzüge und artikel
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US10687785B2 (en) 2005-05-12 2020-06-23 The Trustees Of Columbia Univeristy In The City Of New York System and method for electromechanical activation of arrhythmias
KR101261256B1 (ko) * 2005-05-23 2013-05-07 다우 코닝 코포레이션 사카라이드-실록산 공중합체를 포함하는 퍼스널 케어조성물
DE602006017829D1 (de) * 2005-05-23 2010-12-09 Dow Corning Oberflächenbehandlungszusammensetzungen mit saccharid-siloxan-polymeren
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
KR101457834B1 (ko) * 2005-08-31 2014-11-05 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법
BRPI0615765A2 (pt) 2005-09-07 2011-05-24 Tyco Healthcare curativo para ferimento com reservatório a vácuo
WO2007035721A2 (en) * 2005-09-19 2007-03-29 The Trustees Of Columbia University In The City Of New York Ultrasound method to open blood brain barrier
WO2007038126A1 (en) * 2005-09-21 2007-04-05 Surmodics, Inc. In vivo formed matrices including natural biodegradable polysaccharides and ophthalmic uses thereof
EP1926509B1 (en) * 2005-09-21 2012-01-11 SurModics, Inc. Coatings and articles including natural biodegradable polysaccharides
JP2007089086A (ja) * 2005-09-26 2007-04-05 Sony Ericsson Mobilecommunications Japan Inc 携帯情報端末及び画像管理プログラム
US20070141106A1 (en) * 2005-10-19 2007-06-21 Bonutti Peter M Drug eluting implant
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
CA2630327C (en) 2005-12-08 2015-05-26 Tyco Healthcare Group Lp Biocompatible surgical compositons
WO2007067761A2 (en) * 2005-12-08 2007-06-14 Tyco Healthcare Group Lp Viscosity-reduced sprayable compositions
AU2006321856B2 (en) * 2005-12-08 2013-01-31 Covidien Lp Biocompatible surgical compositions
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
EP1963805A4 (en) * 2005-12-09 2010-01-06 Univ Columbia SYSTEMS AND METHODS FOR ELASTOGRAPHIC IMAGING
CN101365469A (zh) * 2005-12-13 2009-02-11 哈克尼斯药品公司 使用肠抑素治疗肥胖的方法
US20070149457A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Stable solid forms of enterostatin
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
WO2007133758A1 (en) * 2006-05-15 2007-11-22 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
WO2007139812A2 (en) * 2006-05-23 2007-12-06 Dow Corning Corporation Novel silicone film former for delivery of actives
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
US7803148B2 (en) 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
CA2657578A1 (en) * 2006-07-11 2008-01-17 Harkness Pharmaceuticals, Inc. Methods of treating obesity using satiety factors
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
US8043235B2 (en) * 2006-08-22 2011-10-25 Schwartz Donald N Ultrasonic treatment of glaucoma
KR101353144B1 (ko) * 2006-08-22 2014-01-22 도날드 엔. 슈워츠 녹내장을 치료하기 위한 파지형 초음파 기기
US10232064B2 (en) 2006-10-04 2019-03-19 National Cheng Kung University Method for sterilizing biological materials
TW200817055A (en) * 2006-10-04 2008-04-16 Univ Nat Cheng Kung Disinfection method for biomaterial
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
US8491521B2 (en) 2007-01-04 2013-07-23 Celleration, Inc. Removable multi-channel applicator nozzle
US9155703B2 (en) * 2007-03-12 2015-10-13 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US8741316B2 (en) * 2007-03-12 2014-06-03 Board Of Regents, The University Of Texas System Highly porous, recognitive polymer systems
US8821899B2 (en) * 2007-03-12 2014-09-02 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US8771713B2 (en) * 2007-03-12 2014-07-08 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US20080262512A1 (en) * 2007-04-02 2008-10-23 Doheny Eye Institute Thrombolysis In Retinal Vessels With Ultrasound
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
MX2009012231A (es) * 2007-05-18 2009-12-01 Valent Biosciences Corp Formulaciones de cinamaldehido y metodos de uso.
AU2008256444A1 (en) * 2007-05-31 2008-12-04 Biocrates Life Sciences Ag Inflammation and oxidative stress level assay
US20100297249A1 (en) * 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
WO2009020994A2 (en) * 2007-08-06 2009-02-12 Doheny Eye Institute Ultrasound and microbubbles in ocular diagnostics and therapies
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
EP2218446A4 (en) * 2007-11-07 2014-07-30 Kaneka Corp METHOD OF PRODUCING MICROCAPSULES USING SOLID FAT
US20100054981A1 (en) * 2007-12-21 2010-03-04 Board Of Regents, The University Of Texas System Magnetic nanoparticles, bulk nanocomposite magnets, and production thereof
US9242295B2 (en) 2007-12-21 2016-01-26 The Univeristy Of Texas At Arlington Bulk nanocomposite magnets and methods of making bulk nanocomposite magnets
US20090177123A1 (en) * 2007-12-28 2009-07-09 Celleration, Inc. Methods for treating inflammatory disorders
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US7662413B2 (en) * 2008-02-27 2010-02-16 Chung Shan Medical University Extracts of sacred water lotus for the treatment of cancer
JP5569398B2 (ja) * 2008-02-29 2014-08-13 フェッローサン メディカル ディバイス エー／エス 止血および／または創傷治癒を促進するための装置
WO2011035312A1 (en) 2009-09-21 2011-03-24 The Trustees Of Culumbia University In The City Of New York Systems and methods for opening of a tissue barrier
WO2009137689A2 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
WO2009140246A2 (en) 2008-05-12 2009-11-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5596027B2 (ja) 2008-06-18 2014-09-24 レイセオン カンパニー カテーテル
US8771746B2 (en) * 2008-06-19 2014-07-08 Otonomy, Inc. Colloidal suspensions comprising a therapeutic agent and squalene
KR20110040936A (ko) * 2008-07-18 2011-04-20 바이오모드 컨셉츠 인코포레이티드 활성 성분을 방출하는 제품
WO2010014792A2 (en) 2008-07-30 2010-02-04 Sterling Lc Method and device for incremental wavelength variation to analyze tissue
WO2010014977A1 (en) 2008-08-01 2010-02-04 The Trustees Of Columbia University In The City Of New York Systems and methods for matching and imaging tissue characteristics
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
WO2010030819A1 (en) 2008-09-10 2010-03-18 The Trustees Of Columbia University In The City Of New York Systems and methods for opening a tissue
WO2010053916A2 (en) * 2008-11-04 2010-05-14 Sterling Lc Method and device for wavelength shifted imaging
KR101522918B1 (ko) 2009-05-29 2015-05-27 사이덱스 파마슈티칼스, 인크. 사이클로덱스트린 유도체를 포함하는 주사용 멜팔란 조성물 및 이의 제조 및 사용 방법
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
NZ597326A (en) * 2009-07-09 2013-05-31 Oshadi Drug Administration Ltd Matrix carrier compositions, methods and uses
FR2948024B1 (fr) * 2009-07-17 2020-01-10 Centre National De La Recherche Scientifique - Cnrs - Emulsion activable par ultrasons et son procede de fabrication.
US10058837B2 (en) 2009-08-28 2018-08-28 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for production of gas-filled microbubbles
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
WO2011041730A2 (en) * 2009-10-01 2011-04-07 Jacobsen Stephen C Light diffusion apparatus
WO2011041720A2 (en) 2009-10-01 2011-04-07 Jacobsen Stephen C Method and apparatus for manipulating movement of a micro-catheter
US8828028B2 (en) 2009-11-03 2014-09-09 Raytheon Company Suture device and method for closing a planar opening
WO2011075557A1 (en) * 2009-12-16 2011-06-23 The Trustees Of Columbia University In The City Of New York Methods, devices, and systems for on-demand ultrasound-triggered drug delivery
AU2010330751A1 (en) * 2009-12-17 2012-07-19 Nativis, Inc. Aqueous compositions and methods
CA2796375C (en) * 2010-04-12 2018-08-28 Chromaflo Technologies, Corp. Low voc solventborne pigment dispersions compositions for tinting solvent-based coatings
KR101858022B1 (ko) 2010-08-23 2018-05-16 다우 실리콘즈 코포레이션 수성 환경에서 안정한 당 실록산 및 그러한 당 실록산의 제조 및 사용 방법
WO2012051426A2 (en) * 2010-10-15 2012-04-19 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
TW201309346A (zh) * 2011-01-05 2013-03-01 Hospira Inc 噴霧乾燥萬古黴素
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP2014512409A (ja) 2011-04-28 2014-05-22 エスティーシー． ユーエヌエム 標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその使用方法
WO2012162664A1 (en) 2011-05-26 2012-11-29 The Trustees Of Columbia University In The City Of New York Systems and methods for opening of a tissue barrier in primates
WO2013010942A1 (en) * 2011-07-15 2013-01-24 Femalon S.A. Composition and method for treating hpv
CA2842306A1 (en) * 2011-07-19 2013-01-24 Stc.Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
GB201112950D0 (en) 2011-07-27 2011-09-14 Sisaf Ltd A system and method for delivery of an active material
CN104159527B (zh) 2012-03-06 2017-04-12 弗罗桑医疗设备公司 包含止血糊剂的压力容器
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
AU2013275758B2 (en) 2012-06-12 2015-03-12 Ferrosan Medical Devices A/S Dry haemostatic composition
WO2014059170A1 (en) 2012-10-10 2014-04-17 The Trustees Of Columbia University In The City Of New York Systems and methods for mechanical mapping of cardiac rhythm
EP2925298B1 (en) 2012-11-29 2019-05-29 Insmed Incorporated Stabilized vancomycin formulations
WO2014121224A2 (en) * 2013-02-01 2014-08-07 The Trustees Of Dartmouth College Biodegradable iron oxide nanoparticle gel for tumor bed therapy
US20140243712A1 (en) * 2013-02-28 2014-08-28 Doheny Eye Institute Thrombolysis in retinal vessels with ultrasound
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9247921B2 (en) 2013-06-07 2016-02-02 The Trustees Of Columbia University In The City Of New York Systems and methods of high frame rate streaming for treatment monitoring
AU2014283170B2 (en) 2013-06-21 2017-11-02 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US10322178B2 (en) 2013-08-09 2019-06-18 The Trustees Of Columbia University In The City Of New York Systems and methods for targeted drug delivery
CA2920835A1 (en) 2013-08-20 2015-02-26 Anutra Medical, Inc. Syringe fill system and method
US9308165B2 (en) * 2013-08-22 2016-04-12 Therapeutic Vision, Inc. Composition for treating ocular effects of diabetes
US10028723B2 (en) 2013-09-03 2018-07-24 The Trustees Of Columbia University In The City Of New York Systems and methods for real-time, transcranial monitoring of blood-brain barrier opening
US10363324B2 (en) * 2013-11-04 2019-07-30 The South African Nuclear Energy Corporation Limited Pharmaceutical composition
AU2014355072A1 (en) 2013-11-26 2016-06-02 Alliqua Biomedical, Inc. Systems and methods for producing and delivering ultrasonic therapies for wound treatment and healing
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
EP3470094B1 (en) 2013-12-11 2020-07-22 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US9532986B2 (en) 2014-04-08 2017-01-03 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
JP2017513839A (ja) * 2014-04-08 2017-06-01 アラダイム コーポレーション 凍結融解後に薬物ナノ結晶を形成するリポソーム
US10238675B2 (en) 2014-05-15 2019-03-26 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3206726B1 (en) 2014-10-13 2020-05-27 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
AU2015371184B2 (en) 2014-12-24 2020-06-25 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
US9995864B2 (en) * 2015-04-03 2018-06-12 Moxtek, Inc. Wire grid polarizer with silane protective coating
US10534120B2 (en) 2015-04-03 2020-01-14 Moxtek, Inc. Wire grid polarizer with protected wires
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3316930B1 (en) 2015-07-03 2019-07-31 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US12186457B2 (en) 2015-12-10 2025-01-07 University Of Cincinnati Sphingolipid coatings and process for manufacturing sphingolipid coatings effective for inhibiting biofilm formation
WO2017097255A1 (zh) * 2015-12-11 2017-06-15 北京大学第一医院 一种检测h因子浓度的方法及试剂盒
JP6723266B2 (ja) * 2015-12-25 2020-07-15 シャープ株式会社 蓄熱材、これを用いた冷蔵庫および保冷容器
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
WO2019053689A1 (en) * 2017-09-18 2019-03-21 Trend Innovations ENCAPSULATION SYSTEM FOR THE PROLONGED RELEASE OF ACTIVE AGENTS
WO2019118458A1 (en) * 2017-12-11 2019-06-20 Respirogen, Inc. Devices and methods for delivery of oxygen to a wound
CA3086180A1 (en) 2017-12-22 2019-06-27 North Carolina State University Polymeric fluorophores, compositions comprising the same, and methods of preparing and using the same
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN112368028A (zh) 2018-05-09 2021-02-12 弗罗桑医疗设备公司 用于制备止血组合物的方法
CN110201194A (zh) * 2019-07-23 2019-09-06 山东百多安医疗器械有限公司 一种治疗动脉粥样硬化斑块的载药显影微泡及其制备方法
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
CN116367835A (zh) 2020-09-21 2023-06-30 安塔雷斯药品公司 氢化可的松磷酸钠和单硫代甘油的水性药物调配物
US20240342075A1 (en) * 2021-07-26 2024-10-17 Suzanne Ahmed Drug delivery platform for delivery of therapeutics and methods of use and manufacture thereof
EP4496575A1 (en) 2022-03-21 2025-01-29 Antares Pharma, Inc. Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3532500A (en) * 1967-07-25 1970-10-06 Eastman Kodak Co Light sensitive vesicular composition comprising an azido-s-triazine compound
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US4162282A (en) * 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5141738A (en) * 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
JPS6019033A (ja) * 1983-07-12 1985-01-31 Matsumoto Yushi Seiyaku Kk 中空マイクロバル−ンおよびその製法
US4615879A (en) * 1983-11-14 1986-10-07 Vanderbilt University Particulate NMR contrast agents for gastrointestinal application
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4830858A (en) * 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
AU587472B2 (en) * 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
US4684479A (en) * 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US4938947A (en) * 1985-11-01 1990-07-03 Centre National De La Recherche Scientifique (Cnrs) Aerosol composition for in vivo imaging
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US5171755A (en) * 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5194266A (en) * 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5078994A (en) * 1990-04-12 1992-01-07 Eastman Kodak Company Microgel drug delivery system
WO1992006701A1 (en) * 1990-10-18 1992-04-30 Huffstutler, M., Conrad, Jr. Preparation of concentrated fluid symphytum extracts, therapeutic forms and methods of use
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
PT693924E (pt) * 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
EP0862420A4 (en) * 1995-10-13 1999-11-03 Penn State Res Found SYNTHESIS OF DRUG SPRAY DRUG NANOPARTICLES

Also Published As

Publication number Publication date
EP0983060A4 (en) 2002-04-24
US20040091541A1 (en) 2004-05-13
EP0983060A1 (en) 2000-03-08
US20010018072A1 (en) 2001-08-30
WO1998051282A1 (en) 1998-11-19
AU7378798A (en) 1998-12-08
US20020039594A1 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
AR017752A1 (es) Composicion de matriz solida y porosa, metodo para su preparacion y metodo para la liberacion controlada de un agente terapeutico utilizando dichamatriz
WO2008118133A3 (en) Silk microspheres for encapsulation and controlled release
ATE304349T1 (de) Herstellungsverfahren von submikrometerwirkstoffpartikeln
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
DK1214058T3 (da) Fremgangsmåde til opnåelse af mikorpartikler
BR0114909A (pt) Dispositivos de distribuição de drogas transdérmicas possuindo microprotuberâncias revestidas
AR024008A1 (es) Uso de microesferas biodegradables que liberan un agente anticancerigeno, para el tratamiento de glioblastoma, proceso para la preparacion de estasmicroesferas y suspension que contiene a las mismas
CL2012002381A1 (es) Combinacion que comprende (2-hidroxietoxi)-amida del acido 6-(4-bromo-2- fluorofenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico o una sal del mismo y un agente anti-tumoral seleccionado de un grupo definido; uso para tratar un trastorno hiperproliferativo en un mamifero.
BR0313474A (pt) dispositivo de distribuição transdérmica de vacina tendo microprotuberáncias revestidas
ES2134501T5 (es) Composicion farmaceutica conteniendo un soporte fundible y procedimiento para su fabricacion.
AR030655A1 (es) Proceso para fabricar un componente de espuma
AR029667A1 (es) Microesfera de liberacion prolongada para administracion inyectable y procedimiento de preparacion
BR9915536A (pt) Composição e método para cuidados com o tecido
CO5060495A1 (es) Articulo limpiador y acondicionador para la piel o pelo desechable y substancialmente seco que tiene suministro de fragancia mejorado y metodo para su elaboracion
BRPI0921687A8 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
JP2002504522A5 (es)
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
AR012691A1 (es) Sistema terapeutico de liberacion dirigido, metodo de preparacion del mismo y metodo para la liberacion controlada de dicho sistema.
Yang et al. Transdermal drug delivery for hair regrowth
PT1133284E (pt) Um processo para a preparacao de particulas cristalinas
NO20073529L (no) Preparater og fremgangsmater for behandling av tilstander i negleenheten
GB2336110A (en) Method of manufacturing porous matrix-type controlled release systems using emulsion technique
ES2193734T3 (es) Agentes modificantes del humo y filamentos de material para fumar que comprenden agentes modificantes del humo.
SV2003001098A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
AR058298A1 (es) Composicion veterinaria